Recent developments in sterol 14-demethylase inhibitors for Chagas disease

Apt, 1998, Treatment of chronic Chagas’ disease with itraconazole and allopurinol, Am. J. Trop. Med. Hyg., 59, 133, 10.4269/ajtmh.1998.59.133 Bahia, M.T. 2011. Anti-T. cruzi activities of benznidazole and posaconazole, used alone or in combination, in a murine model of acute Chagas disease. 27th Meeting on Applied Research on Chagas Disease, Uberaba, MG, Brazil. Buckner, 2003, A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents, Proc. Natl. Acad. Sci. USA, 100, 15149, 10.1073/pnas.2535442100 Buckner, 2008, Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections, Adv. Exp. Med. Biol., 625, 61, 10.1007/978-0-387-77570-8_6 Campoli, 2011, Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis, Antimicrob. Agents Chemother., 55, 5732, 10.1128/AAC.00637-11 Chen, 2009, Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit, PLoS Negl. Trop. Dis., 3, e372, 10.1371/journal.pntd.0000372 Chen, 2010, Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole, PLoS Negl. Trop. Dis., 4, e651, 10.1371/journal.pntd.0000651 Clayton, 2010, Chagas Disease: Pushing Through the Pipeline, Nature, 465, S12, 10.1038/nature09224 Corrales, 2005, Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease, Antimicrob. Agents Chemother., 49, 1556, 10.1128/AAC.49.4.1556-1560.2005 Daum, 1998, Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae, Yeast, 14, 1471, 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y Diniz, 2010, Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi, Antimicrob. Agents Chemother., 54, 2979, 10.1128/AAC.01742-09 Docampo, 1981, Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi, Mol. Biochem. Parasitol., 3, 169, 10.1016/0166-6851(81)90047-5 Doyle, 2010, A nonazole CYP51 inhibitor cures Chagas’ disease in a mouse model of acute infection, Antimicrob. Agents Chemother., 54, 2480, 10.1128/AAC.00281-10 Fischer, 1989, Mechanistic studies of lanosterol 14 alpha-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme, J. Lipid Res., 30, 1621, 10.1016/S0022-2275(20)38245-6 Furlong, 1989, Sterols of parasitic protozoa and helminths, Exp. Parasitol., 68, 482, 10.1016/0014-4894(89)90134-3 Gascon, 2010, Chagas disease in Spain, the United States and other non-endemic countries, Acta Trop., 115, 22, 10.1016/j.actatropica.2009.07.019 Guedes, 2004, Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts, Antimicrob. Agents Chemother., 48, 4286, 10.1128/AAC.48.11.4286-4292.2004 Hargrove, T.Y., Wawrzak, Z., Liu, J., Waterman, M.R., Nes, W.D., Lepesheva, G.I., 2011. Structural complex of sterol 14alpha-demethylase (CYP51) with 14alpha-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol. J. Lipid Res. (Epub ahead of print). Hucke, 2005, The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease, J. Med. Chem., 48, 5415, 10.1021/jm050441z Konkle, 2009, Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase, J. Med. Chem., 52, 2846, 10.1021/jm801643b Korn, 1969, The sterols of Trypanosoma cruzi and Crithidia fasciculata, Comp. Biochem. Physiol., 30, 601, 10.1016/0010-406X(69)92137-9 Kraus, 2009, Rational modification of a candidate cancer drug for use against Chagas disease, J. Med. Chem., 52, 1639, 10.1021/jm801313t Kraus, 2010, Second generation analogues of the cancer drug clinical candidate Tipifarnib for anti-chagas disease drug discovery, J. Med. Chem., 53, 3887, 10.1021/jm9013136 Lepesheva, 2006, CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B’ helix defines substrate preferences of sterol 14alpha-demethylase, J. Biol. Chem., 281, 3577, 10.1074/jbc.M510317200 Lepesheva, 2007, Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth, Chem. Biol., 14, 1283, 10.1016/j.chembiol.2007.10.011 Lepesheva, 2010, Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi, J. Biol. Chem., 285, 25582, 10.1074/jbc.M110.133215 Lepesheva, 2008, CYP51: a major drug target in the cytochrome P450 superfamily, Lipids, 43, 1117, 10.1007/s11745-008-3225-y Lepesheva, 2010, Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections, J. Biol. Chem., 285, 1773, 10.1074/jbc.M109.067470 Lepesheva, 2011, Targeting Trypanosoma cruzi sterol 14alpha-demethylase (CYP51), Adv. Parasitol., 75, 65, 10.1016/B978-0-12-385863-4.00004-6 Leslie, 2011, Infectious diseases. A tropical disease hits the road, Science, 333, 934, 10.1126/science.333.6045.934 Liendo, 1998, In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(−) enantiomer against Trypanosoma cruzi, J. Antimicrob. Chemother., 41, 197, 10.1093/jac/41.2.197 Liendo, 1999, Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes, Mol. Biochem. Parasitol., 104, 81, 10.1016/S0166-6851(99)00129-2 Marin-Neto, 2007, Pathogenesis of chronic Chagas heart disease, Circulation, 115, 1109, 10.1161/CIRCULATIONAHA.106.624296 Molina, 2000, Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts, Antimicrob. Agents Chemother., 44, 150, 10.1128/AAC.44.1.150-155.2000 Pinazo, 2010, Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus, Am. J. Trop. Med. Hyg., 82, 583, 10.4269/ajtmh.2010.09-0620 Rassi, 2010, Chagas disease, Lancet, 375, 1388, 10.1016/S0140-6736(10)60061-X Urbina, 2011, New insights in Chagas’s disease treatment, Drug Future, 35, 409, 10.1358/dof.2010.035.05.1484391 Urbina, 2010, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Trop., 115, 55, 10.1016/j.actatropica.2009.10.023 Urbina, 2003, Specific chemotherapy of Chagas disease: controversies and advances, Trends Parasitol., 19, 495, 10.1016/j.pt.2003.09.001 Urbina, 1996, Cure of short- and long-term experimental Chagas’ disease using D0870, Science, 273, 969, 10.1126/science.273.5277.969 Urbina, 1998, Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies, Antimicrob. Agents Chemother., 42, 1771, 10.1128/AAC.42.7.1771 Urbina, 2003, In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease, Int. J. Antimicrob. Agents, 21, 27, 10.1016/S0924-8579(02)00273-X Urbina, 2003, Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains, Int. J. Antimicrob. Agents, 21, 39, 10.1016/S0924-8579(02)00274-1 Urbina, 2004, In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi, Antimicrob. Agents Chemother., 48, 2379, 10.1128/AAC.48.7.2379-2387.2004 Viotti, 2006, Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial, Ann. Intern. Med., 144, 724, 10.7326/0003-4819-144-10-200605160-00006 Viotti, 2011, Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease, PLoS Negl. Trop. Dis., 5, e1314, 10.1371/journal.pntd.0001314 Walker, 1993, Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering, J. Med. Chem., 36, 2235, 10.1021/jm00067a022 Williams, 2001, Termination of development of D0870, J. Antimicrob. Chemother., 47, 720, 10.1093/oxfordjournals.jac.a002691